-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Founder Peng Liang Just Bought A Handful Of Shares In Clover Biopharmaceuticals, Ltd. (HKG:2197)
Founder Peng Liang Just Bought A Handful Of Shares In Clover Biopharmaceuticals, Ltd. (HKG:2197)
Whilst it may not be a huge deal, we thought it was good to see that the Clover Biopharmaceuticals, Ltd. (HKG:2197) Founder, Peng Liang, recently bought HK$549k worth of stock, for HK$1.83 per share. Nevertheless, it only increased their shareholding by a minuscule percentage, and it wasn't a massive purchase by absolute value, either.
See our latest analysis for Clover Biopharmaceuticals
Clover Biopharmaceuticals Insider Transactions Over The Last Year
In fact, the recent purchase by Founder Peng Liang was not their only acquisition of Clover Biopharmaceuticals shares this year. Earlier in the year, they paid HK$1.92 per share in a HK$1.2m purchase. That means that even when the share price was higher than HK$1.84 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Peng Liang was the only individual insider to buy during the last year.
Peng Liang bought a total of 918.00k shares over the year at an average price of HK$1.89. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
SEHK:2197 Insider Trading Volume October 16th 2022There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Insider Ownership Of Clover Biopharmaceuticals
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that Clover Biopharmaceuticals insiders own 22% of the company, worth about HK$470m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
What Might The Insider Transactions At Clover Biopharmaceuticals Tell Us?
It is good to see the recent insider purchase. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Once you factor in the high insider ownership, it certainly seems like insiders are positive about Clover Biopharmaceuticals. Looks promising! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Clover Biopharmaceuticals. You'd be interested to know, that we found 1 warning sign for Clover Biopharmaceuticals and we suggest you have a look.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
虽然这可能不是什么大问题,但我们认为很高兴看到 三叶草生物制药有限公司 (HKG: 2197) 创始人彭亮最近以每股1.83港元的价格购买了价值54.9万港元的股票。尽管如此,这只是将他们的持股量增加了微不足道的百分比,而且按绝对价值计算,这也不是一次大规模的收购。
查看我们对 Clover Biopharmaceuticals 的最新分析
Clover Biopharmaceuticals 去年的内幕交易
事实上,创始人彭亮最近的收购并不是他们今年唯一一次收购三叶草生物制药的股票。今年早些时候,他们在120万港元的收购中支付了每股1.92港元。这意味着,即使股价高于1.84港元(最近的价格),也有内部人士想购买股票。尽管自收购以来,他们的看法可能发生了变化,但这至少表明他们对公司的未来充满信心。在我们看来,内部人士为股票支付的价格非常重要。令人鼓舞的是,内部人士的股票价格高于当前价格,这表明即使在更高的水平上,他们也看到了价值。彭亮是去年唯一买入的个人内部人士。
彭亮全年共购买了918.00万股股票,平均价格为1.89港元。您可以在下图中看到过去一年的内幕交易(公司和个人)。如果你想确切地知道谁卖了、卖了多少以及何时出售,只需点击下图即可!
联交所:2197 2022年10月16日内幕交易量还有很多其他公司有内部人士买入股票。你可能这样做 不 想错过这个 免费的 内部人士正在收购的成长型公司名单。
三叶草生物制药的内部所有权
对于普通股股东来说,值得检查一下公司内部人士持有多少股票。较高的内部所有权通常会使公司领导层更加关注股东的利益。Clover Biopharmaceuticals的内部人士似乎拥有该公司22%的股份,价值约4.7亿港元。尽管内部所有权水平很高,但并不突出,但这足以表明管理层和小股东之间存在一定的一致性。
Clover Biopharmaceuticals 的内幕交易会告诉我们什么?
很高兴看到最近的内幕收购。而长期的内幕交易也给我们带来了信心。但是,我们注意到,该公司在过去十二个月中没有盈利,这使我们持谨慎态度。考虑到内部人士的高所有权,内部人士似乎对三叶草生物制药持乐观态度。看起来很有希望!除了了解正在进行的内幕交易外,识别Clover Biopharmaceuticals面临的风险也是有益的。你会有兴趣知道的,我们发现了 三叶草生物制药有 1 个警告标志 我们建议你看看。
当然, 你可能会在其他地方找到一笔不错的投资。 所以来看看这个 免费的 有趣的公司名单。
就本文而言,内部人士是指向相关监管机构报告交易的个人。我们目前用于公开市场交易和私人处置,但不包括衍生品交易。
对这篇文章有反馈吗?对内容感到担忧? 取得联系 直接和我们联系。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是一般性的。 我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章无意提供财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能未将最新的价格敏感型公司公告或定性材料考虑在内。简而言之,华尔街对上述任何股票都没有头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧